Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants

A Randomized, Open-Label, 3-Period, Single-Dose, Cross-Over Study in Healthy Participants to Assess the Relative Bioavailability of AGMB-129 Given as Tablet Formulation Versus the Capsule Reference Formulation and to Assess the Effect of Food on Tablet Formulation

This is a single-center, open-label, single-dose, randomized, 3-period cross-over, Phase 1 study in healthy adult participants to assess the BA of AGMB-129 tablet formulation relative to that of the reference capsule formulation and to assess the effect of food on the BA of a single oral dose of the AGMB-129 tablet formulation.

A total of 24 participants will be enrolled. Participants will be randomized to 1 of 6 intervention sequences (Williams design) according to a 6-sequence, 3-period design. In 3 sequential intervention periods, each participant will receive 3 study interventions, 1 in each intervention period. The total duration of involvement for each participant, screening through follow-up, will be approximately 6 weeks.

Study Overview

• Status: Completed
• Conditions: Healthy Volunteers
• Intervention / Treatment: Drug: AGMB-129

• Study Type: Interventional
• Enrollment (Actual): 25
• Phase: Phase 1

Contacts and Locations

Study Locations

• Belgium
  • Edegem, Belgium
    • SGS Belgium

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Key Inclusion Criteria:

1. Male or female, between 18 and 55 years old (extremes included) on the date of signing the ICF.
2. Body weight of at least 50.0 kg for men and 45.0 kg for women, and a body mass index (BMI) between 19.0 and 30.0 kg/m2 (extremes included) at screening.
3. Must be in good health based on medical history, physical examination, vital signs, and 12-lead ECG in the opinion of the investigator at screening.
4. Total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) must be ≤1.5x upper limit of normal (ULN) at screening. Other clinical laboratory safety test results must be within the reference ranges or test results that are outside the reference ranges need to be considered not clinically significant in the opinion of the investigator. Note: Participants with diagnosed Gilbert's syndrome with total bilirubin >1.5 ULN are eligible for the study if AST and ALT are ≤1.5x ULN.

Key Exclusion Criteria:

1. Known hypersensitivity to AGMB-129 ingredients or history of a significant allergic reaction to AGMB-129 ingredients as determined by the investigator.
2. Positive serology for hepatitis B virus surface antigen (HBsAg) or anti-hepatitis C virus [HCV] antibodies at screening, or history of hepatitis from any cause except for hepatitis A that was resolved at least 3 months prior to the first IP administration.
3. History of or a current immunosuppressive condition, including positive human immunodeficiency virus types 1 or 2 (HIV-1 [2]) antibodies at screening.
4. Current or history of vasculitis, valvular heart disease, or large vessel vascular disease (such as aneurism or dissection) at screening.
5. Any illness, judged by the investigator as clinically significant, in the 3 months prior to the first IP administration.
6. Presence or sequelae of gastrointestinal, liver, kidney (estimated glomerular filtration rate [eGFR] ≤80 mL/min/1.73 m² using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs at screening.
7. History of malignancy within the past 5 years prior to screening, except for excised and curatively treated non-metastatic basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of cervix which is considered cured with minimal risk of recurrence.
8. History or presence of clinically significant abnormalities detected on 12-lead ECG of either rhythm or conduction, e.g., known long QT syndrome or a QT interval corrected for heart rate according to Fridericia's formula (QTcF) >450 ms detected on the 12-lead ECG at screening or Day 1 predose. A first-degree atrioventricular block will not be considered as a clinically significant abnormality.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1; ABC with A=oral capsule under fed conditions B=oral tablet under fasted conditions C=oral tablet under fed conditions	Drug: AGMB-129; Each participant will receive 3 study interventions, 1 in each intervention period
Experimental: 2; CAB with A=oral capsule under fed conditions B=oral tablet under fasted conditions C=oral tablet under fed conditions	Drug: AGMB-129; Each participant will receive 3 study interventions, 1 in each intervention period
Experimental: 3; BCA with A=oral capsule under fed conditions B=oral tablet under fasted conditions C=oral tablet under fed conditions	Drug: AGMB-129; Each participant will receive 3 study interventions, 1 in each intervention period
Experimental: 4; CBA with A=oral capsule under fed conditions B=oral tablet under fasted conditions C=oral tablet under fed conditions	Drug: AGMB-129; Each participant will receive 3 study interventions, 1 in each intervention period
Experimental: 5; BAC with A=oral capsule under fed conditions B=oral tablet under fasted conditions C=oral tablet under fed conditions	Drug: AGMB-129; Each participant will receive 3 study interventions, 1 in each intervention period
Experimental: 6; ACB with A=oral capsule under fed conditions B=oral tablet under fasted conditions C=oral tablet under fed conditions	Drug: AGMB-129; Each participant will receive 3 study interventions, 1 in each intervention period

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Cmax for AGMB-129	From baseline to Day 3
Cmax for MET-158	From baseline to Day 3
Cmax for MET-154	From baseline to Day 3
AUC0-t for AGMB-129	From baseline to Day 3
AUC0-t for MET-158	From baseline to Day 3
AUC0-t for MET-154	From baseline to Day 3
AUC0-∞ for AGMB-447	From baseline to Day 3
AUC0-∞ for MET-158	From baseline to Day 3
AUC0-∞ for MET-154	From baseline to Day 3

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with adverse events	To evaluate the safety and tolerability of AGMB-129 in terms of adverse events at every visit	From Screening to Day 5
Number of participants with abnormal clinical laboratory values	To evaluate the safety and tolerability of AGMB-129 in terms of abnormal laboratory parameters at every visit	From Screening to Day 5
Number of participants with abnormal vital signs	To evaluate the safety and tolerability of AGMB-129 in terms of vital signs at every visit	From Screening to Day 5
Number of participants with abnormal physical exams	To evaluate the safety and tolerability of AGMB-129 in terms of physical exams at every visit	From Screening to Day 5

Collaborators and Investigators

• Sponsor: Agomab Spain S.L.
• Investigators: Study Director: Philippe Wiesel, MD, Agomab Therapeutics

Study record dates

Study Major Dates

• Study Start (Actual): April 2, 2024
• Primary Completion (Actual): May 8, 2024
• Study Completion (Actual): May 13, 2024

Study Registration Dates

• First Submitted: April 30, 2024
• First Submitted That Met QC Criteria: May 2, 2024
• First Posted (Actual): May 3, 2024

Study Record Updates

• Last Update Posted (Actual): May 16, 2024
• Last Update Submitted That Met QC Criteria: May 15, 2024
• Last Verified: May 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: AGMB-129-C103

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No